Israeli AI genomics startup Genoox acquired by Qiagen in $80 million deal
Franklin platform will expand reach of AI-powered clinical decision support in genetic testing.
German diagnostics company Qiagen has announced the acquisition of Genoox, an Israeli-founded provider of AI-powered software for clinical genetic testing, in a deal valued at $80 million. The acquisition underscores the rising strategic value of advanced bioinformatics platforms as genetic testing becomes increasingly routine in clinical care.
Founded in 2014 by Amir Trabelsi and Moshe Einhorn, later joined by Yuval Porat and Oron Lev, Genoox developed Franklin, a cloud-based platform designed to support small and mid-sized laboratories in analyzing next-generation sequencing (NGS) data. The platform uses AI to interpret complex genetic information in real time, helping clinicians diagnose inherited diseases, guide cancer treatments, and inform reproductive decisions.
Franklin is currently used by more than 1,700 healthcare organizations across 50 countries and has facilitated over 150,000 clinical case interpretations to date. Its widespread adoption reflects the growing demand for accessible tools that can handle the escalating complexity and volume of genomic data.
The acquisition strengthens Qiagen’s Digital Insights portfolio, adding to existing products such as QCI Interpret and QCI Precision Insights, as well as the company’s proprietary genetic variant databases COSMIC and HGMD.
For Genoox, the sale marks a significant milestone after raising $26 million from venture firms including Glilot Capital Partners, TriVentures, Inimiti, IMED, The Group Ventures, Artofin, and IN Ventures.
“The acquisition of Genoox brings together two complementary strengths to better serve clinical testing laboratories,” said Qiagen CEO Thierry Bernard in a statement. “Franklin’s AI-powered solution offers exciting opportunities for labs to rapidly identify the most clinically relevant insights and help improve patient outcomes.”
“Joining Qiagen marks a major milestone in our mission to make genomic data more accessible and impactful,” said Amir Trabelsi, Co-founder and CEO of Genoox. “Franklin will benefit from Qiagen’s global reach and scientific leadership as we scale to support more labs and patients around the world. As part of Qiagen, we can together drive the next wave of precision medicine.”
